As Zepbound shortage grows, Eli Lilly says there's no immediate end in sight [MSNBC.com]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MSNBC.com
Despite Eli Lilly’s assurances about an ample supply of its new weight loss drugZepboundThe Food and Drug Administrationapproved Zepboundblockbuster weight loss drug WegovyZepbound officially went into shortage in April, according to the FDA, mere months after Lilly CEO Dave Rickstold NBC Newsthe FDA’s websiteLilly is blaming the shortage on the huge demand for the drug, saying it can’t produce enough to meet everyone’s needs for diabetes and for weight loss.Like Zepbound, all but one dosage of Mounjaro is in shortage, according to the FDA.“For the near term, we are going to be in this limited availability, which may cause delays across some of the doses for both Mounjaro and Zepbound,” said Rhonda Pacheco, Lilly’s group vice president for diabetes and obesity. “We are working so hard every day to make sure that we increase that capacity as fast as we can to get these medications in patients’ hands.”It’s unclear when exactly that will be.To increase supply, Lilly said it plans to open
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at BMO Capital Markets from $900.00 to $1,001.00. They now have an "outperform" rating on the stock.MarketBeat
- Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise [Seeking Alpha]Seeking Alpha
- ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $850.00 to $900.00. They now have an "overweight" rating on the stock.MarketBeat
- Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Truist Financial Co. from $850.00 to $892.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- 4/16/24 - Form 4
- LLY's page on the SEC website